NCT00136409

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.

Detailed description

Gleevec will be administered at a dose of 400 mg orally once daily. Patients will continue to receive the drug until either drug progression or the development of intolerable side effects. Patients will be assessed with a complete blood count weekly for the first 8 weeks and will have monthly physical examinations and bone marrow examinations every 3 months.

Conditions

• Myelofibrosis
• Myeloid Metaplasia
• Agnogenic Myeloid Metaplasia
• Chronic Myelomonocytic Leukemia

Interventions

Type	Name	Description
DRUG	Imatinib mesylate	400mg orally once daily until disease progression or unacceptable side effects

Timeline

• Start date: 2002-05-01
• Primary completion: 2005-08-01
• Completion: 2008-12-01
• First posted: 2005-08-29
• Last updated: 2016-12-23

Locations

2 sites across 1 country: United States